EGFR targeting in hormone-refractory prostate cancer: Current appraisal and prospects for treatment

Pharmaceuticals

Volumn 3, Issue 7, 2010, Pages 2238-2247

  Guérin, Olivier ^a,b,c   Fischel, Jean Louis ^a   Ferrero, Jean Marc ^a,c   Bozec, Alexandre ^a   Milano, Gerard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b University of Côte d'Azur   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Chemotherapy; EGFR; Geriatric oncology; Hormone resistant prostate cancer; Kinase inhibitors; Prostate cancer; Targeted therapy

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IRINOTECAN; LUTETIUM 177; MONOCLONAL ANTIBODY; PLACEBO; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; VANDETANIB;

ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; HORMONE RESISTANCE; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN TARGETING; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING;

EID: 77955677151     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3072238     Document Type: Review

References (53)

1. Jemal, A.; Siegel, R.; Ward, E. Cancer statistics. Cancer J. Clin. 2008, 58, 71-96.
2. Tannock, I.F.; Osoba, D.; Stockler, M.R.; Ernst, D.S.; Neville, A.J.; Moore, M.J.; Armitage, G.R.; Wilson, J.J.; Venner, P.M.; Coppin, C.M.; Murphy, K.C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996, 14, 1756-1764.
3. Tannock, I.F.; De Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Theodore, C.; James, N.D.; Turesson, I.; Rosenthal, M.A.; Eisenberg, M.A. TAX 327 investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone fot advanced prostate cancer. N. Eng. J. Med. 2004, 351, 1502-1512.
4. Paule, B.; Brion, N. EGF receptors in urological cancer. Molecular basis and therapeutic involvements. Ann. Med. Intern. 2003, 154, 448-456.
5. Salomon, D.S.; Brandt, R.; Ciardello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183-232.
6. Bianco, R.; Melisi, D.; Ciardiello, F.; Tortora, G. Key cancer cell signal transduction pathways as therapeutic targets. Eur. J. Cancer 2006, 42, 290-294.
7. Modi, S.; Seidman, A.D. An update on epidermal growth factor receptor inhibitors.Curr. Oncol. Rep. 2002, 4, 47-55.
8. Baselga, J. The EGFR as a target for anticancer therapy-focus on cetuximab.Eur. J. Cancer 2001, 37 (Suppl 4), S16-22.
9. Herbst, R.S.; Kim, E.S.; Harari, P.M. IMC-C225, An anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert. Opin.Biol.Ther. 2001, 1, 719-732.
10. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 2003, 21(12), 2237-2246.
11. Ranson, M.; Hammond, L.A.; Ferry, D.; Kris, M.; Tullo, A.; Murray, P.I.; Miller, V.; Averbuch, S.; Ochs, J.; Morris, C.; et al. A selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 2002, 2, 2240-2250.
12. Bonomi, P. Erlotinib: A new therapeutic approach for non-small cell lung cancer. Expert. Opin. Invest. Drugs 2003, 12, 1395-1401.
13. Herbst, R.S. Erlotinib (Tarceva): an update on the clinical trial program. Semin. Oncol. 2003, 3 (Suppl 7), 34-46.
14. Fan, Z.; Lu, Y.; Wu, X.; Mendelsohn, J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. 1994, 269, 27595-27602.
15. Prewett, M.; Rockwell, P.; Rockwell, R.F.; Giorgio, N.A.; Mendelsohn, J.; Scher, H.I.; Goldstein, N.I. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother Emphasis Tumor Immunol. 1996, 19, 419-427.
16. Ciardiello, F.; Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001, 7, 2958-2970.
17. Denny, W.A. Irreversible inhibitors of the erbB family of protein tyrosine kinases. Pharmacol. Ther. 2002, 93, 253-261.
18. Noonberg, S.B.; Benz, C.C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000, 59, 753-767.
19. Arteaga, C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 2001, 19 (Suppl. 18), 32S-40S.
20. Fan, Z.; Shang, B.Y.; Lu, Y.; Chou, J.L.; Mendelsohn, J. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin. Cancer Res. 1997, 3, 1943-1948.
21. Kiyota, A.; Shintani, S.; Mihara, M.; Nakahara, Y.; Ueyama, Y.; Matsumura, T.; Tachikawa, T.; Wong, D.T. Anti-epidermal growth factor receptor monoclonal antibody 225 upregulatesp27(KIP1) and p15(INK4B) and induces G1 arrest in oral squamous carcinoma cell lines. Oncology 2002, 63, 92-98.
22. Huang, S.M.; Bock, J.M.; Harari, P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59, 1935-1940.
23. Huang, S.M.; Harari, P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 2000, 6, 2166-2174.
24. Tortora, G.; Caputo, R.; Damiano, V.; Bianco, R.;Fontanini, G.; Cuccato, S.; De Placido, S.; Bianco, A.R.;Ciardiello, F. Oral administration of a novel taxane, ananti sense oligo nucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin. Cancer Res. 2001, 7, 4156-4163.
25. Goldstein, N.I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1, 1311-1318.
26. Bleeker,W.K.; Lammerts van Bueren,J.J.; van Ojik, H.H.;. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 2004,173, 4699-4707.
27. Milano G. Pharmacological skills for targeting EGFR and VEGF. Bull Cancer 2005, 92, S17-20.
28. Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; De Placido, S.; Bianco, A.R.; Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839, anepidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000, 6, 2053-2063.
29. Magné, N.; Fischel,J.L.; Dubreuil, A.; Formento, P.; Poupon, M.F.; Laurent-Puig, P.; Milano, G. Influence of epidermal growth factor receptor (EGFR), and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839. Br. J. Cancer 2002, 86, 1518-1523.
30. Magné, N.; Fischel,J.L.; Dubreuil, A.; Formento, P.; Marcié, S.; Lagrange,J.L.; Milano, G. Sequence-dependent effects of ZD1839 in combination with cytotoxic treatment in human head and neck cancer. Br. J. Cancer 2002, 86, 819-827.
31. Prewett, M.C.; Hooper, A.T.; Bassi, R.; Ellis, L.M.; Waksal, H.W.; Hicklin, D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumorxenografts. Clin. Cancer Res. 2002, 8, 994-1003.
32. Bruns, C.J.; Harbison, M.T.; Davis, D.W.; Portera, C.A.; Tsan, R.; McConkey, D.J.; Evans, D.B.; Abbruzzese, J.L.; Hicklin, D.J.; Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 2000, 6, 1936-1948.
33. Han, S.W.; Kim, T.Y.; Hwang, P.G.; Jeong, S.; Kim, J.; Choi, I.S.; Oh, D.Y.; Kim, J.H.; Kim, D.W.; Chung, D.H.; Im, S.A.; Kim, Y.T.; Lee, J.S.; Heo, D.S.; Bang, Y.J.; Kim, N.K. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 2005, 23, 2493-2501.
34. Buter, J.; Giaccone, G. EGFR inhibitors in lung cancer. Oncology 2005, 19, 1707-1712, 1720-1723.
35. Folprecht, G.; Lutz, M.P.; Schoffski, P.; Seufferlein, T.; Nolting, A.; Pollert, P.; Kohne, C.H. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol.2006, 17, 450-456.
36. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M.S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E.K.; And, K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2006, 354, 567-578.
37. Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Humblet, Y.; Lopez-Pousa, A.; Hitt, R.; Vega, M.E.; et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2006, 24, 2866-2872.
38. Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Lee, D.; Wang, V.; Leysens, M.; Higgins, B.; Martin, J.; et al. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000, 60, 6134-6141.
39. Di Lorenzo, G.; Tortora, G.; D'Armiento, F.P.; De Rosa, G.; Staibano, S.; Autorino, R.; D'Armiento, M.; De Laurentiis, M.; De Placido, S.; Catalano, G.; et al. Expression of epidermal growth factor receptor is correlated with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 2002, 8, 3438-3444.
40. Schlomm, T.; Kirstein, P.; Iwers, L.; Daniel, B.; Steuber, T.; Walz, J.; Chun, F.H.; Haese, A.; Kollermann, J.; Graefen, M.; et al. A. Clinical Significance of Epidermal Growth Factor Receptor protein overexpression and gene copy number gains in prostate cancer. Clin. Cancer Res. 2007, 13, 6579-6584.
41. Zhau, H.E.; Wan, D.S.; Zhou, J.; Miller, G.J.; Von Eschenbach, A.C. Expression of c-erbB2/neu protooncogene in human prostatic cancer tissues and cell line. Mol. Carcinol. 1992, 5, 320-327.
42. Cho, K.S.; Lee, J.S.; Cho, N.H.; Park, K.; Ham, W.S.; Choi, Y.D. Gene amplification and mutation analysis of Epidermal Growth Factor Receptor in hormone refractory prostate cancer. Prostate 2008, 68, 803-808.
43. Hammarsten, P.; Halin, S.; Wikstöm, P.; Henriksson, R.; Haggstrom Rudolfsson, S.; Bergh, A. Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin. Cancer Res. 2006, 12, 7431-7436.
44. Guérin, O.; Formento, P.; Lo Nigro, C.; Hofman, P.; Fischel, J.L.; Etienne-Grimaldi, M.C.; Merlano, M.; Ferrero, J.M.; Milano, G. Supra-additive antitumor effects of sunitinibmalate combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J. Cancer Res. Clin. Oncol. 2008, 134, 51-57.
45. Kelly, M.P.; Lee, S.T.; Lee, F.T.; Smyth, F.E.; Davis, I.D.; Brechbiel, M.W.; Scott, A.M. Therapeutic efficacy of 177Lu-CHX-A-DTPA-hu3S193 radio immune therapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate 2009, 69, 926104.
46. Gravis, G.; Bladou, F.; Salem, N.; Gonçalves, A.; Esterni, B.; Walz, J.; Bagattini, S.; Marcy, M.; Brunelle, S.; Viens, P. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann. Oncol. 2008, 19, 1624-1628.
47. Canil, C.M.; Moore, M.J.; Winquist, E.; Baetz, T.; Pollak, M.; Chi, K.N. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 2005, 23, 455-460.
48. She, Q.B.; Solit, D.; Basso, A.; Mark M. Moasser. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive PI3K/Akt pathway signaling. Clin. Cancer Res. 2003, 9, 4340-4346.
49. Weihua, Z.; Tsan, R.; Huang, W.C.; Wu, Q.; Chiu, C.H.; Fidler, I.J.; Hung, M.C. Survival of cancer cells is maintained by EGFR independant of its kinase activity. Cancer Cell 2008, 13, 385-393.
50. Chiorean, E.G.; Porter, J.M.; Foster, A.E.; Al Omari, A.S.; Yoder, C.A.; Fife, K.L.; Strother, R.M.; Murry, D.J.; Yu, M.; Jones, D.R.; Sweeny, C.J. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin. Cancer Res. 2008, 14, 1131-1137.
51. Gross, M.; Higano, C.; Pantuck, A.; Castellanos, O.; Green, E.; Nguyen, K.; Agus,A.B.A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007, 7, 142-148.
52. Horti, J.; Widmark, A.; Stenzi, A.; Federico, M.H.; Abratt, R.P.; Sanders, N.; Pover, G.M.; Bodrogi, I. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother. Radiopharm. 2009, 24, 175-180.
53. Droz, J.P.; Balducci, L.; Bolla, M.; Emberton, M.; Fitzpatrick, J.M.; Joniau, S.; Kattan, M.W.; Monfardini, S.; Moul, J.W.; Naeim, A.; Van Poppel, H.; Saad, F.; Sternberg, C.N. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit.Rev. Oncol. Hematol. 2010, 73, 68-91.